CN1279014C - 具有抗血管生成、抗肿瘤和促凋亡活性的类维生素a衍生物 - Google Patents

具有抗血管生成、抗肿瘤和促凋亡活性的类维生素a衍生物 Download PDF

Info

Publication number
CN1279014C
CN1279014C CNB028150082A CN02815008A CN1279014C CN 1279014 C CN1279014 C CN 1279014C CN B028150082 A CNB028150082 A CN B028150082A CN 02815008 A CN02815008 A CN 02815008A CN 1279014 C CN1279014 C CN 1279014C
Authority
CN
China
Prior art keywords
purposes
compound
tumor
cells
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB028150082A
Other languages
English (en)
Chinese (zh)
Other versions
CN1537094A (zh
Inventor
L·默里尼
S·达尔拉维勒
S·潘科
G·吉安尼尼
C·皮萨诺
L·维斯丝
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11455702&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1279014(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Publication of CN1537094A publication Critical patent/CN1537094A/zh
Application granted granted Critical
Publication of CN1279014C publication Critical patent/CN1279014C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/54—Unsaturated compounds containing hydroxy or O-metal groups containing six-membered aromatic rings and other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/72—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings and other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C62/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C62/30—Unsaturated compounds
    • C07C62/32—Unsaturated compounds containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/732—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734—Ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
CNB028150082A 2001-07-31 2002-07-18 具有抗血管生成、抗肿瘤和促凋亡活性的类维生素a衍生物 Expired - Fee Related CN1279014C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITRM2001A000464 2001-07-31
IT2001RM000464A ITRM20010464A1 (it) 2001-07-31 2001-07-31 Derivati retinoidi ad attivita' antiangiogenica, antitumorale e pro-apoptotica.

Publications (2)

Publication Number Publication Date
CN1537094A CN1537094A (zh) 2004-10-13
CN1279014C true CN1279014C (zh) 2006-10-11

Family

ID=11455702

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB028150082A Expired - Fee Related CN1279014C (zh) 2001-07-31 2002-07-18 具有抗血管生成、抗肿瘤和促凋亡活性的类维生素a衍生物

Country Status (19)

Country Link
US (2) US8101793B2 (https=)
EP (1) EP1412317B1 (https=)
JP (1) JP4463550B2 (https=)
KR (1) KR100888466B1 (https=)
CN (1) CN1279014C (https=)
AT (1) ATE492526T1 (https=)
AU (1) AU2002326144B2 (https=)
BR (1) BR0211521A (https=)
CA (1) CA2454532C (https=)
CY (1) CY1114535T1 (https=)
DE (1) DE60238683D1 (https=)
DK (1) DK1412317T3 (https=)
ES (1) ES2358097T3 (https=)
HU (1) HU229308B1 (https=)
IT (1) ITRM20010464A1 (https=)
MX (1) MXPA04000877A (https=)
PL (1) PL207530B1 (https=)
PT (1) PT1412317E (https=)
WO (1) WO2003011808A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104496839A (zh) * 2014-12-03 2015-04-08 广东东阳光药业有限公司 取代环丁烷类神经氨酸酶抑制剂及其使用方法和用途

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060062786A1 (en) * 2000-11-08 2006-03-23 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US20030228309A1 (en) * 2000-11-08 2003-12-11 Theodora Salcedo Antibodies that immunospecifically bind to TRAIL receptors
US20050214209A1 (en) * 2001-05-25 2005-09-29 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US20050129616A1 (en) * 2001-05-25 2005-06-16 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
US7361341B2 (en) * 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
US20090226429A1 (en) * 2001-05-25 2009-09-10 Human Genome Sciences, Inc. Antibodies That Immunospecifically Bind to TRAIL Receptors
ITRM20010464A1 (it) * 2001-07-31 2003-01-31 Sigma Tau Ind Farmaceuti Derivati retinoidi ad attivita' antiangiogenica, antitumorale e pro-apoptotica.
EP1456165A1 (en) * 2001-11-30 2004-09-15 The Burnham Institute Induction of apoptosis in cancer cells
CA2471140A1 (en) * 2001-12-20 2003-07-03 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
CA2598518C (en) 2005-02-22 2015-04-21 Ranbaxy Laboratories Limited 5-phenyl-pentanoic acid derivatives as matrix metalloproteinase inhibitors for the treatment of asthma and other diseases
FR2884248B1 (fr) * 2005-04-08 2007-05-18 Galderma Res & Dev Nouveau procede de preparation de l'acide 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphtoique
JP5155148B2 (ja) * 2005-04-08 2013-02-27 ガルデルマ・リサーチ・アンド・デヴェロップメント ６−［３−（１−アダマンチル）−４−メトキシフェニル］−２−ナフトエ酸の合成方法
ITRM20050248A1 (it) * 2005-05-20 2006-11-21 Sigma Tau Ind Farmaceuti Uso acido adamantil metossidifenil propenoico per il trattamento di patologie cutanee.
JP5080462B2 (ja) 2005-06-28 2012-11-21 シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ ビフェニルおよびナフチル−フェニルヒドロキサム酸誘導体
WO2007037188A1 (ja) * 2005-09-27 2007-04-05 Sapporo Medical University 血管透過性亢進に起因する眼疾患の予防及び治療のための医薬
WO2007071605A1 (en) * 2005-12-19 2007-06-28 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. The use of st1898 for the treatment of restenosis
JP5054006B2 (ja) * 2006-06-23 2012-10-24 ロート製薬株式会社 ヒアルロン酸産生促進能を有する組成物
US20100330200A1 (en) * 2006-12-22 2010-12-30 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Combination of a retinoid and a platinum anticancer agent
WO2010000784A1 (en) * 2008-07-03 2010-01-07 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Treatment of restenosis
TW201031402A (en) * 2008-12-24 2010-09-01 Sigma Tau Ind Farmaceuti New retinoid derivatives endowed with cytotoxic and/or antiangiogenic properties
WO2010096264A2 (en) 2009-02-03 2010-08-26 Children's Medical Center Corporation Methods for enhancing hematopoietic stem/progenitor cell engraftment
WO2010091052A2 (en) 2009-02-03 2010-08-12 Children's Medical Center Corporation Methods for enhancing hematopoietic stem/progenitor cell engraftment
WO2010106135A1 (en) 2009-03-20 2010-09-23 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Combined use for the treatment of ovarian carcinoma
CN102892755A (zh) 2009-12-23 2013-01-23 韦恩州立大学 治疗性化合物
AU2012311640B2 (en) * 2011-09-19 2017-04-13 Alfasigma S.P.A. New thio derivatives bearing lactams as potent HDAC inhibitors and their uses as medicaments
JP5757602B2 (ja) * 2012-05-11 2015-07-29 国立大学法人金沢大学 不斉選択性の切り替えが可能なクロマトグラフィー用充填剤
WO2017053778A1 (en) 2015-09-25 2017-03-30 Fuchs Helen Burgwyn Antibacterial and antifungal compounds
AU2017208970A1 (en) 2016-01-18 2018-08-02 Arisan Therapeutics Adamatane derivatives for the treatment of filovirus infection
EP3301085A1 (en) * 2016-09-29 2018-04-04 Biogem S.Ca.R.L. Retinoid derivatives with antitumor activity
WO2018201074A1 (en) * 2017-04-27 2018-11-01 Vanderbilt University Methods for treating atherosclerosis with gamma-ketoaldehyde scavengers
US11278025B2 (en) 2017-05-17 2022-03-22 The General Hospital Corporation Antibiotic compounds
WO2019018185A1 (en) 2017-07-15 2019-01-24 Arisan Therapeutics Inc. ENANTIOMERICALLY PURE ADAMATANE DERIVATIVES FOR THE TREATMENT OF FILOVIRUS INFECTIONS
IT201900003343A1 (it) * 2019-03-07 2020-09-07 Special Product’S Line S P A Derivati fenolici per uso come antimicrobici, antibatterici, battericidi
CN111956806B (zh) * 2020-09-03 2023-04-07 四川大学 一种药物载体、胶束、药剂及其制备方法和应用
IT202000029882A1 (it) * 2020-12-04 2022-06-04 Special Product’S Line S P A Derivati fenolici per uso come antimicrobici, antibatterici, battericidi
IT202000029906A1 (it) * 2020-12-04 2022-06-04 Special Product’S Line S P A Derivati fenolici per uso come antimicrobici, antibatterici, battericidi.
WO2022229017A1 (en) 2021-04-27 2022-11-03 Biogem S.C.A R.L. Adamantyl retinoid derivative with anticancer activity

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2676052B1 (fr) * 1991-05-02 1994-04-29 Cird Galderma Nouveaux composes polycycliques aromatiques et leur utilisation en medecine humaine ou veterinaire et en cosmetique.
IL127946A0 (en) * 1996-07-08 2000-02-17 Cird Galderma Apoptosis inducing adamantyl derivatives and their usage as anti-cancer agents
ITRM20010464A1 (it) * 2001-07-31 2003-01-31 Sigma Tau Ind Farmaceuti Derivati retinoidi ad attivita' antiangiogenica, antitumorale e pro-apoptotica.
EP1456165A1 (en) * 2001-11-30 2004-09-15 The Burnham Institute Induction of apoptosis in cancer cells

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104496839A (zh) * 2014-12-03 2015-04-08 广东东阳光药业有限公司 取代环丁烷类神经氨酸酶抑制剂及其使用方法和用途
CN104496839B (zh) * 2014-12-03 2016-04-20 广东东阳光药业有限公司 取代环丁烷类神经氨酸酶抑制剂及其使用方法和用途

Also Published As

Publication number Publication date
JP2004536879A (ja) 2004-12-09
CY1114535T1 (el) 2016-10-05
JP4463550B2 (ja) 2010-05-19
AU2002326144B2 (en) 2008-04-10
ATE492526T1 (de) 2011-01-15
US20040235757A1 (en) 2004-11-25
ES2358097T3 (es) 2011-05-05
MXPA04000877A (es) 2004-06-03
US8101793B2 (en) 2012-01-24
US20080021088A1 (en) 2008-01-24
CA2454532C (en) 2011-01-25
ITRM20010464A1 (it) 2003-01-31
EP1412317B1 (en) 2010-12-22
DE60238683D1 (de) 2011-02-03
PT1412317E (pt) 2011-03-21
HK1068868A1 (en) 2005-05-06
US7449495B2 (en) 2008-11-11
PL368412A1 (en) 2005-03-21
WO2003011808A1 (en) 2003-02-13
PL207530B1 (pl) 2010-12-31
CA2454532A1 (en) 2003-02-13
CN1537094A (zh) 2004-10-13
HU229308B1 (en) 2013-10-28
HUP0401604A2 (hu) 2004-12-28
HUP0401604A3 (en) 2006-01-30
KR100888466B1 (ko) 2009-03-12
KR20040028968A (ko) 2004-04-03
BR0211521A (pt) 2004-09-14
ITRM20010464A0 (it) 2001-07-31
EP1412317A1 (en) 2004-04-28
DK1412317T3 (da) 2011-03-28

Similar Documents

Publication Publication Date Title
CN1279014C (zh) 具有抗血管生成、抗肿瘤和促凋亡活性的类维生素a衍生物
CN1173945C (zh) 5-硫代-ω-取代的苯基-前列腺素E衍生物、其制备方法及含有它们作为活性成分的药物
CN1042026C (zh) 维生素d系列的25羧酸衍生物、其制法及中间产物、含该衍生物的药物及其药用
CN1031992C (zh) 苯醌衍生物及其药用
CN1218943C (zh) 4－嘧啶基－n－酰基－l－苯基丙氨酸类化合物
CN1320599A (zh) 受限的9－顺－视黄酸类
CN1900067A (zh) 三环化合物及其制备和用途
CN1227466A (zh) 用作神经氨酸酶抑制剂的取代环戊烷化合物
CN1088581A (zh) 内皮素受体拮抗剂
CN1342140A (zh) 硫代酰胺衍生物
CN1291978A (zh) 作为整联蛋白拮抗剂的间－氮杂环氨基苯甲酸化合物及其衍生物
CN1200699C (zh) 蒽酮衍生物及其在淀粉样变性中的用途
CN1231472C (zh) 嘧啶无环核苷衍生物、其制备方法及其用途
CN1310716A (zh) 作为基质金属蛋白酶抑制剂的三环磺胺化合物及其衍生物
CN1617854A (zh) 苯基(烷基)羧酸衍生物和二酸苯基烷基杂环衍生物及其用作具有血清葡萄糖和/或血清脂降低活性的药物的应用
CN1079788C (zh) 酰胺衍生物及其在治疗上的应用
CN1073563C (zh) 4,6－二叔丁基－2,3－二氢苯并噻吩衍生物
CN1187360C (zh) 有羧基肽酶b抑制活性的膦酸衍生物
CN1819990A (zh) 具有抗hcv作用的化合物及其制法
CN1091733A (zh) 抗雄性激素的单环烯烃和双环烯烃
CN1744892A (zh) 乳癌耐性蛋白(bcrp)抑制剂
CN1075809C (zh) 新的维生素d类似物
HK1068868B (en) Retinoid derivatives with antiangiogenic, antitutmoral and proapoptotic activities
CN1167678C (zh) 新颖的维生素d类似物
CN1289323A (zh) 基质金属蛋白酶抑制剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1068868

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20061011

Termination date: 20140718

EXPY Termination of patent right or utility model